Solutions and Recommendations

Psychedelic therapy access needs more than approval. The field needs evidence plans, payment models, delivery infrastructure, professional training, and equity safeguards that can work inside real health systems.

The recommendations here focus on four connected areas: stronger clinical and economic evidence, clearer regulatory and HTA planning, workable treatment infrastructure, and access models that do not depend only on private payment.

The drug-plus-therapy model is the recurring challenge. Health systems need to know who is responsible, what is being paid for, how quality is checked, and how outcomes are followed after treatment.

Use these recommendations as a planning checklist for developers, providers, payers, regulators, patient groups, and policy teams. The common thread is simple: solve evidence, payment, and delivery together.

Build evidence for the whole care model

Evidence plans for psychedelic therapies need to cover the treatment package, not only the medicine. Trial design, psychological support, safety monitoring, follow-up, and service resource use all affect whether a payer can assess value.

Progress depends on early coordination between developers, regulators, HTA bodies, providers, payers, patient groups, and public research funders. The goal is to avoid discovering after approval that the evidence package cannot answer the access questions.

For drug developers

• Use active placebo, crossover, or other trial designs only when they answer a clear evidence question and do not create new interpretation problems.

• Plan 6-12 month follow-up for relapse, retreatment, ongoing care, resource use, and safety, then connect that evidence to registries where routine care begins.

• Where possible, compare psychedelic treatments with the care that payers actually expect to be displaced, especially in markets such as Germany where comparator choice can shape benefit assessment.

• Use pilots in receptive countries to learn about referral, site capacity, workforce, outcomes tracking, and payment before assuming a model can scale nationally.

• Track functional recovery, quality of life, work, hospital use, caregiver burden, and service use so the value case does not rely only on symptom scores.

• Engage with regulators and payer assessment bodies (HTA groups) during Phases II and III to align evidence collection and analyses with requirements.

Design trials with access in mind

Regulators and evaluators will expect credible trials, including designs that address functional unblinding. Active placebos, such as low doses of the study drug, can help; Compass Pathways has already used this approach. Developers should keep discussing acceptable active-placebo designs with the EMA, even when those designs add cost and complexity.

Crossover studies, where participants receive both treatment and placebo at different times, can be an effective trial design. These studies are efficient because each person acts as their own control. However, developers must carefully consider how long psychedelic effects last when planning these trials.

Adaptive designs can help when regulators agree on decision rules before the trial starts. Pragmatic trials and real-world studies can then answer questions that late-stage approval trials rarely settle: which protocol works in routine care, which patients need more support, and which delivery choices make the model sustainable.

Trials should make the drug and support model legible. Developers need to show what the medicine contributes, what the psychological support contributes, and why the selected protocol is clinically and economically defensible.

Real-world pilots can complement trials when they are built with regulators, payers, and providers. They should test referral, site capacity, outcomes, cost, safety, and scalability, not only show that a service can run in one motivated setting.

Post-market authorisation evidence generation

Developers need evidence on both short-term response and durability. Trials should track symptoms for 6-12 months where possible, while post-launch registries can follow relapse, retreatment, safety, and healthcare use in routine care.

Registry studies can supplement clinical trials after launch, especially in countries that expect reassessment. They should track outcomes that matter for access: durability, retreatment, adverse events, resource use, and patient selection.

Close the evidence gaps payers will see

Developers should focus on evidence that fits HTA expectations: validated measures for quality of life, functional recovery, and symptom reduction. Economic models should also capture indirect benefits such as productivity gains, reduced caregiver burden, and lower hospitalisation rates. Countries such as the Netherlands may take a broader view of value, but developers still need early payer advice to avoid conflicts between regulatory endpoints and reimbursement criteria.

In many markets, especially Germany, reimbursement depends on comparison with the care that would otherwise be used: SSRIs, augmentation therapies, ketamine, psychotherapy, or other standard options. If direct comparisons are not feasible, developers need to explain the limits of the alternative design.

For therapies with high uncertainty, conditional reimbursement or managed entry agreements that link reimbursement to real-world performance can help address payer concerns while providing earlier patient access. Starting with pilot submissions in smaller markets can help test and refine evidence packages before targeting larger countries.

For regulators and evaluators

• Publish clearer trial-design expectations and make early consultation easier to access.

• Support shared registries and core outcome measures so countries can compare evidence more easily.

• Coordinate regulatory and reimbursement evidence expectations where possible, especially for long-term outcomes and service-model data.

• Define unmet-need criteria for mental-health treatments so incentives are tied to clear patient groups, not broad field enthusiasm.

Give developers clearer guidance

Developers need clearer guidance on how psychedelic evidence will be judged. Existing regulatory and HTA frameworks help, but they do not fully address blinding, psychological support, site requirements, long sessions, or post-launch data needs.

Access incentives should be tied to clear definitions of unmet need. Mental-health conditions carry high personal and societal burden, but developers still need to show which patient groups lack adequate options. Those definitions can then support routes such as PRIME designation, accelerated assessment, conditional marketing authorisation, or additional data protection.

Regulators can make early advice more useful by opening consultation before patient trials begin. Those meetings should cover practical trial-design questions such as blinding, comparator choice, and country-specific standards of care. Smaller developers will need affordable routes into these discussions, otherwise early advice will mainly benefit better-funded companies.

Make evidence easier to compare

Regulators and evaluators should accept appropriate innovative designs when they answer the decision problem. Crossover, hybrid, pragmatic, and registry-linked designs can help, but only if the assumptions are explicit and the resulting evidence is interpretable.

Shared outcome metrics would reduce duplicate studies and make evidence easier to compare across countries. Regulators can allow flexibility while still setting clear expectations for data transparency, post-marketing surveillance, and core outcomes. That gives developers a clearer evidence target and gives payers a more consistent basis for review.

Model cost, value, and uncertainty explicitly

Economic evaluation has to reflect the real product: medicine plus care. The model should show upfront treatment cost, service cost, durability, retreatment, downstream healthcare use, and broader outcomes where the local HTA system allows them.

Developers need economic models that show value in terms HTA bodies can use. Assessment bodies also need ways to evaluate therapies where the medicine, psychological support, clinic time, and follow-up are part of one intervention. The shared task is to make uncertainty visible: durability of benefit, comparator evidence, redosing, staffing, and service costs should be modelled rather than left for payers to infer.

Where broader societal benefits are excluded from the base case, developers should still present them transparently as supplementary evidence. That helps payers see the full value story without pretending every country will count it the same way.

For drug developers

• Model the full episode: medicine, therapy time, rooms, monitoring, integration, follow-up, retreatment, and relevant downstream costs.

• Build country-specific versions for markets where cost-effectiveness drives reimbursement, especially the UK and the Netherlands.

• Use scenario and sensitivity analyses for durability, treatment effect, retreatment, uptake, staffing, and eligible population size.

• Assess market viability early by checking each country's HTA methods, thresholds, budget rules, and treatment comparators.

• Engage HTA bodies before the model is locked, so assumptions can be adjusted while trials and evidence plans can still change.

Build the full economic model

A complete model should include direct treatment costs and, where relevant, wider effects such as productivity, caregiver burden, hospitalization, medication use, and crisis-care use.

QALYs remain central in many markets, so mental-health outcomes need to translate into utility measures that HTA bodies accept. Scenario testing should show which assumptions decide the result.

Adapt the model by market

Developers should not assume one economic model will travel unchanged. NICE, ZiN, G-BA, SUKL, and other bodies use different perspectives, thresholds, and budget questions.

In some markets, budget impact will be the main focus of the economic evaluation. The scope may include drug cost only, drug plus therapy, or the full cost of delivering care.

Plan market entry around payer requirements

Market sequencing should follow the evidence fit. A country with clear methods but a demanding comparator may be harder than a smaller market that can test the service model through pilots or managed access.

For HTA evaluators and payers

• Create methods for assessing combined drug-therapy care, including service cost, long-term outcomes, and broader value where the local system permits it.

• Use bundled payments, staged payments, or outcomes-linked contracts when upfront cost and long-term uncertainty make standard reimbursement too blunt.

• Set evidence expectations with developers early, including acceptable economic models, comparator choices, and real-world data plans.

• Agree on core real-world outcome fields so evidence collected after launch can support reassessment, not just local reporting.

Adapt HTA frameworks for combined care

HTA frameworks should evaluate the drug and therapy components as one practical care model. Methods can stay nationally specific while still naming the evidence needed for service cost, staffing, durability, and indirect value.

Use payment models that match the service

Payers should avoid drug-only payment designs when the therapy requires structured care. Bundles, staged payments, and outcome-based contracts can help if they are simple enough for providers to use and clear enough for payers to audit.

Create early dialogue channels

Early dialogue should include HTA bodies, payers, developers, providers, and patient groups. The point is to align evidence requirements with service reality before the launch file is already fixed.

Build real-world evidence deliberately

Real-world evidence programmes should start with a decision question: durability, safety, retreatment, resource use, or subgroup fit. The dataset should be built around that question, not collected because registries sound useful.

Regulatory and policy reforms

Psychedelic therapies will test rules built mainly for conventional medicines. Existing frameworks can handle product quality, safety, and efficacy, but they need clearer treatment of controlled-substance operations, therapy protocols, and post-launch monitoring.

Developers, regulators, and policymakers each own part of the access problem. Developers can use existing routes and show where they fail. Regulators can protect patients while clarifying expectations for combined drug-therapy models. Policymakers can decide how publicly funded systems balance safety, innovation, and access.

For drug developers

• Use expedited pathways like EMA’s PRIME and MHRA’s ILAP, and pursue conditional approvals to speed up the regulatory process while collecting real-world evidence.

• Consider decentralised approval approaches through national authorities before broader European expansion.

• Start early dialogue with regulators to align on trial designs and evidence requirements for these novel treatments.

• Build data collection systems that address both regulatory and HTA requirements from the start.

Using accelerated regulatory pathways

Developers should consider expedited regulatory pathways such as EMA PRIME and MHRA ILAP when they fit the evidence plan. These programs can create earlier feedback, but they do not remove the need for post-launch evidence and payer-ready data.

Using multiple regulatory pathways

Developers should compare centralised and decentralised approval strategies early. The EMA centralised procedure offers broad market access, while decentralised or mutual-recognition routes can sometimes start from a reference member state. For psychedelic therapies, this can matter when some countries are more receptive to novel treatment models than others.

Enhancing dialogue with regulators

Regular scientific-advice meetings, including with the EMA's Scientific Advice Working Party, can prevent avoidable delays. Early dialogue is especially useful for placebo controls, therapy protocols, comparator choice, and evidence expectations. Developers should also speak with national bodies because country requirements can differ after European approval.

Safety plans should go beyond standard pharmacovigilance. Developers need controlled-substance risk plans, therapist and site training, adverse-event reporting, emergency-response procedures, and clear rules for patient follow-up. Those details give regulators and providers a concrete basis for judging whether a service can operate safely.

Stakeholder engagement is useful when it answers implementation questions. Patient groups, providers, and payers should help define outcomes, service requirements, and evidence gaps, while scientific standards remain explicit.

For regulators

• Consider bifurcated scheduling models that enable medical use while maintaining controls for recreational use.

• Develop clear frameworks for post-approval evidence collection and conditional marketing authorisations.

• Strengthen coordination between national authorities to facilitate efficient mutual recognition procedures for psychedelic therapies.

• Strengthen collaboration between regulators, HTA groups, and international agencies to streamline development.

Scheduling should allow medical use

Scheduling reform should separate medical use from non-medical use. A bifurcated model can keep controls while allowing authorised clinical care, similar to frameworks used for ketamine or sodium oxybate.

Research exemptions can also reduce friction before full rescheduling. They should make legitimate studies easier while keeping storage, handling, and safety requirements clear.

Post-approval evidence should be planned before launch

Pre-approval access may be limited by controlled-substance scheduling, so post-approval evidence systems become especially important. Conditional approval models can allow earlier market entry while requiring real-world studies after launch. The conditions should spell out what evidence is needed on outcomes, safety, durability, service use, and effectiveness.

Harmonise where it reduces duplicated work

Countries can keep their own decision authority while sharing evaluation criteria, post-approval evidence expectations, and safety learning. Harmonisation is most useful where it reduces duplicate work without flattening local access decisions.

Align regulatory and HTA advice

Regulatory and HTA alignment helps developers avoid building an approval file that cannot support reimbursement. Joint advice, template protocols, and clear agency contact points can make the drug-plus-therapy model easier to assess.

Coordinate internationally where evidence can transfer

International coordination can reduce duplicated evidence work, especially for safety monitoring, registry design, and trial methods. It should not be treated as a replacement for country-specific payer and delivery planning.

Build delivery infrastructure around the care episode

Implementation needs more than approval. Health systems need rooms, trained roles, referral pathways, quality controls, pharmacy handling, monitoring, and payment models that match the service patients actually receive.

Countries will face different constraints, but the recurring questions are the same: where treatment happens, who delivers it, how staff are trained, how safety is managed, and who pays for the non-drug parts of care.

For healthcare systems and providers

• Create treatment rooms that are calm, private, monitorable, and usable for several-hour sessions without blocking ordinary clinic flow.

• Use public, insurer, provider, and private funding partnerships where one actor cannot carry facility upgrades alone.

• Plan capacity around long sessions: staffing, room scheduling, referral volume, and expected retreatment.

• Join professional networks and training programmes while pushing for recognised, affordable certification routes.

• Define screening, deferral, aftercare, and emergency support before opening the pathway.

• Work toward shared European standards for therapy delivery and qualifications while allowing local adaptation.

• Build relationships with local mental health services to ensure proper patient referrals and emergency support when needed.

• Track outcomes and adverse events in a way that can improve practice and support payer review.

• Participate in multi-disciplinary working groups to define optimal and minimum acceptable care package standards.

• Study group formats, task-sharing, and other delivery models only with clear safety and quality controls.

Infrastructure development

Many mental-health facilities lack spare rooms suited to extended psychedelic therapy sessions. These sessions need calm, private, monitorable spaces where patients can remain for several hours without blocking ordinary clinic flow.

Funding and partnerships can help build infrastructure. Insurers, governments, providers, and private investors may each fund different parts of the model, but the business case should show how rooms, staff, outcomes, and patient access improve.

Define the treatment package

Working groups should define both optimal and minimum acceptable care packages: room setup, preparation, dosing support, integration, monitoring, escalation, documentation, and staff roles.

Training and professional development

Therapist and facilitator capacity is one of the main limits on scale. Several training programmes exist, but they are not yet recognised or accredited by most national health systems. That creates uncertainty for practitioners, providers, and payers. Public systems will need training standards that combine online learning, supervised practice, and clear competency checks without making certification prohibitively expensive.

Training pathways need supervision, continuing education, competency checks, and financial support. Subsidies or tax incentives may help build capacity faster, especially in public systems.

Clinical operations and quality assurance

Clinical operations need named protocols: screening, contraindications, risk assessment, dosing-day monitoring, integration, adverse-event response, and documentation.

European systems need delivery standards for dosing, preparation, integration, risk management, and professional roles. Those standards should define qualifications, training, supervision, and continuing education. Clear standards make services easier to commission and give patients and providers more confidence.

Quality assurance should track outcomes, adverse events, protocol adherence, supervision, and patient experience. Professional networks can then compare learning across sites and update practice as evidence accumulates.

Scale up through referral, pharmacy, and emergency pathways

Service expansion needs planning across referral pathways, provider roles, emergency support, pharmacy handling, and controlled-substance storage. Medicine-management systems should meet regulatory requirements without making day-to-day clinical delivery unworkable.

Scale-up planning should tie workforce, facility expansion, reimbursement, and outcome tracking together. Regular review of cost and outcomes helps show whether the service is ready to move beyond early sites.

For payers

• Develop billing codes and payment structures that accommodate extended therapy sessions combined with novel drug treatments, following examples like the U.S. CPT codes for psychedelic therapy.

• Create outcome-based payment models linking reimbursement to clinical improvements and reduced healthcare utilisation.

• Establish commercial access programs with real-world monitoring to evaluate cost-effectiveness before full implementation.

• Partner with providers to develop standardised outcome measures and documentation requirements for reimbursement.

Payment structures for the full episode

Payers need payment structures for a combined medicine-and-care episode. U.S. CPT code work shows one possible route: define administration and monitoring time rather than treating psychedelic therapy as an ordinary prescription.

Bundled payments can simplify administration when they cover medicine, preparation, dosing, integration, monitoring, and follow-up. Outcomes-linked contracts may help when payers accept the clinical case but worry about durability.

Cost management

Flexible pricing should be practical, not only innovative. Staged payments, outcome-linked pricing, or managed access need clear outcomes, workable reporting, and enough provider cash flow to deliver the service.

Implementation pilots

Pilots should test real-world effectiveness, cost, throughput, documentation, and payment mechanics before broader rollout. A pilot that cannot inform reimbursement is only a demonstration.

Monitoring that payers can use

Monitoring should include standard outcomes, service use, adverse events, patient experience, and documentation requirements. The data should be useful for reassessment and payment decisions.

For drug developers

• Focus on developing clear, practical service specifications in partnership with healthcare stakeholders, which are specific enough to reassure healthcare systems but flexible enough to allow local adaptation.

• Avoid over-engineering treatment requirements beyond regulatory mandates.

• Support retrofitting of existing healthcare facilities rather than creating separate centers of excellence.

• Maintain clear boundaries between drug development responsibilities and healthcare system implementation.

Infrastructure support

Developers do not need to build every service themselves. Their useful role is to give providers practical specifications for spaces, monitoring, storage, staffing, referral criteria, and follow-up.

Keep treatment requirements practical

Protocols should be specific enough to support safety but flexible enough for local health systems. Overly narrow requirements can create unnecessary workforce and facility bottlenecks.

Other mental-health treatments show why support requirements should be clear but not overprescribed. Developers can define the essential treatment frame while letting health systems adapt delivery details responsibly.

Market development through service specifications

Market development works best when developers provide a service specification that health systems can adopt: minimum safety standards, facility needs, staff roles, training expectations, and room for local variation.

Professional support

Developers can train providers on product-specific information, but health systems and professional bodies should lead broader therapy training and certification. Developers could help fund independent training groups without controlling the curriculum. That separation supports trust while still speeding up workforce development.

Make trust and safeguards part of implementation

Psychedelic therapy implementation also depends on trust. Services need consent rules, therapist boundaries, adverse-event reporting, cultural competence, and fair access plans, not only rooms and reimbursement.

Providers should own ethical delivery standards. Policymakers should make sure access does not depend only on wealth, geography, or private clinics.

For healthcare providers

• Develop specialised informed consent protocols that address altered states and psychological vulnerability during treatment sessions.

• Create clear boundaries and safety guidelines for therapist-patient relationships before, during and after psychedelic sessions.

• Establish real-time reporting systems for psychological adverse events and integration challenges.

• Build support networks for providers to share experiences and develop best practices for ethical challenges.

Consent for altered states

Providers need protocols for caring for patients during altered states. Consent should explain the psychological experiences and risks patients may encounter. Screening and support plans should pay particular attention to people with trauma histories, substance-use histories, or other vulnerabilities.

Providers need plain consent, screening, monitoring, emergency response, documentation, and integration plans. These should be written for altered-state care, not copied from ordinary medicine consent forms.

Boundaries and integration

Psychedelic therapy needs explicit boundary rules for altered states and integration. Protocols should define physical presence, touch, emotional support, communication after sessions, and escalation when patients need extra help.

Professional networks should keep these boundary questions live through supervision, case review, and shared learning, not leave each clinic to improvise alone.

For policymakers

• Create funding mechanisms to support treatment access in rural areas and for economically disadvantaged populations.

• Develop initiatives to diversify the therapist workforce and provide culturally appropriate care.

• Build decentralised care networks to reach underserved communities.

• Mandate collection of demographic data to track and address treatment access disparities.

Geographic and economic access

Access planning should look beyond wealthy urban centres. Regional hubs, supported referral networks, and mobile or shared-care models may help reach patients outside major cities.

Cultural competency and workforce diversity

Culturally competent care needs more than translated materials. It requires workforce diversity, community engagement, language access, and protocols that respect different beliefs about altered states and mental-health care.

Equity cannot be managed without data. Services should track who is referred, who is accepted, who completes treatment, who benefits, who drops out, and where adverse events occur.

Track who receives care

Country playbooks

Germany

Germany: where to focus first

• Engage G-BA and IQWiG early so comparator choice, endpoints, and patient-relevant outcomes fit German benefit assessment.

• Build the evidence case around added benefit versus the German standard of care, not only versus placebo.

• Use managed-entry or risk-sharing only where the remaining uncertainty can be measured through real-world outcomes.

• Start rollout in specialist hospital or university settings where governance, monitoring, and high-cost care are already easier to manage.

• Prepare rooms, storage, supervision protocols, and emergency procedures before reimbursement decisions create demand.

• Use registries or post-launch monitoring to track durability, retreatment, safety, and service use.

• Let psychiatric and psychotherapy associations shape training standards so the workforce route is credible inside German care.

• Build professional legitimacy through clinical guidelines, early academic sites, and psychiatric leadership rather than broad public enthusiasm alone.

• Use public-private partnerships where infrastructure, training, or data collection costs are too large for one actor to carry.

Professional adoption

Germany's psychiatric community may move cautiously. Education should focus on evidence, safety, patient selection, and service governance, not field advocacy.

Professional organisations can reduce prescriber uncertainty by helping define guidance, training expectations, and appropriate-use criteria.

Natural-product framing may interest some audiences, especially for psilocybin, but it should not replace a rigorous medical message on quality control, safety, and evidence.

Regulatory and clinical pathway

Germany's framework, overseen by BfArM and shaped by G-BA and IQWiG assessment, rewards early attention to comparative evidence. Developers should discuss evidence expectations early and consider trials against recognised comparators such as SSRIs, cognitive behavioural therapy, or other relevant standard treatments. Naturalistic studies can complement RCTs by showing how the therapy performs in real-world German care.

Developers should plan for long-term data from the start: durability, relapse, retreatment, safety, and resource use. Adaptive or hybrid designs can help only if they still answer German comparator questions.

Evidence and monitoring

Germany's health technology assessment process, led by G-BA and IQWiG, requires strong Phase III randomised controlled trial data demonstrating clear added therapeutic benefit compared to existing treatments. This comparative effectiveness evidence forms the foundation for reimbursement and pricing decisions under the AMNOG process.

Real-world evidence can support long-term monitoring and safety data collection, but it cannot replace high-quality RCT results. Post-launch registries and observational studies can track long-term outcomes, but developers still need decisive Phase III data showing comparative effectiveness against appropriate standard care.

Registries and observational studies are useful after launch, but they should complement the Phase III evidence package rather than substitute for it.

German public funding already signals serious interest. The BMBF-funded EPIsoDE psilocybin study and related implementation research give future access planning a stronger local evidence base.

Public-private evidence partnerships can help other countries too, provided they produce payer-relevant data rather than only academic outputs.

Reimbursement and financial modelling

Germany's statutory health insurance system rewards evidence of added benefit over standard care. That matters because many mental-health comparators are low-cost generics, while psychedelic therapy may involve a higher medicine price plus staff-intensive care. Developers need pharmacoeconomic analyses that test whether higher upfront costs are offset by fewer admissions, lower later service use, or better sustained outcomes.

Risk-sharing agreements and managed-entry models can address payer concerns about upfront cost and evidence uncertainty. These agreements link reimbursement to observed outcomes. Developers can strengthen the case by tracking reduced hospitalisations, lower use of other treatments, or other service offsets, as seen in German esketamine evidence for TRD.

Specialist psychiatric outpatient departments are a practical early setting because they already manage high-cost therapies and clinical governance. They can support controlled rollout, data collection, and protocol adherence. Germany adds a separate payment problem: private physician-led outpatient clinics operate under tight reimbursement constraints. Insurers would need specific arrangements to pay predictably for the medicine, extended therapist time, and initial evaluation.

Workforce development and infrastructure

Scaling psychedelic therapies in Germany requires investment in workforce training and infrastructure. Clinical and psychiatric associations should define therapist certification with developer input, so training matches protocols while staying aligned with German clinical standards. Competency-based modules, similar to frameworks used in CAR-T implementation, can support adoption without weakening quality controls.

Infrastructure work should be practical: fund rooms that meet safety, privacy, supervision, storage, and patient-flow requirements. Pilots can show what scales and what does not.

Because long sessions strain rooms and staff, German providers should test safe efficiency gains such as group preparation, shared monitoring where appropriate, or better scheduling before demand grows.

Public-private support

Partnerships with insurers, government bodies, providers, and private investors can share the cost of facility upgrades, training, and data systems.

Policy support should be tied to concrete access bottlenecks: workforce, rooms, evidence infrastructure, and fair patient eligibility.

United Kingdom

United Kingdom: where to focus first

• Use ILAP or similar routes when early contact with regulators and NHS partners can improve the evidence and adoption plan.

• Engage NICE, SMC, and NHS England early on comparators, cost-effectiveness modelling, service cost, and real-world evidence expectations.

• Consider the Innovative Medicines Fund only where the remaining uncertainty is specific enough for managed access to answer.

• Use head-to-head evidence where feasible, or design indirect comparisons that can withstand NICE and SMC scrutiny.

• Build long-term follow-up around relapse, medication use, service use, quality of life, and economic sustainability.

• Design payment models that share risk without making the service too administratively heavy for NHS providers.

• Plan rooms, monitoring, pharmacy handling, and training inside NHS trust workflows, not as a separate boutique service.

• Test group, hybrid, or other delivery models inside NHS settings before treating them as national scale solutions.

• Use pilots to refine care pathways, service cost, documentation, and economic assumptions before national rollout.

Regulatory and NHS engagement

The UK's Innovative Licensing and Access Pathway (ILAP) can give promising therapies earlier contact with the health system. Five psychedelic developers[26]1 have received ILAP designations, creating opportunities to discuss evidence generation, NHS adoption, and NICE expectations before launch. NICE advice remains important because regulatory approval alone will not answer payer questions about comparators, economic modelling, service costs, and outcomes that matter to the NHS.

The NHS Innovative Medicines Fund can support conditional access while further data are collected. Entry is limited to products with plausible clinical value and cost-effectiveness, and NICE and NHS England act as gatekeepers. A similar temporary-access logic may be useful for psychedelic therapies if the remaining uncertainty is about durability, service cost, or real-world delivery rather than basic safety.

Trial design and evidence

UK reimbursement will depend on comparative effectiveness. Where feasible, developers should use head-to-head trials against existing treatments so NICE can assess incremental cost-effectiveness. If direct comparison is not feasible, the trial still needs to support credible indirect comparisons and include outcomes that matter to the NHS, such as hospitalisation, quality of life, function, and caregiver burden.

Long-term follow-up should capture relapse, medication use, NHS resource use, quality of life, and functional outcomes over time.

NHS-linked registries can test whether trial results hold in routine services and whether the model is scalable at acceptable cost.

Economics and reimbursement

NICE thresholds make the full service cost central. Economic models should include drug cost, rooms, clinical time, monitoring, integration, and plausible downstream savings. Generic ketamine may have a different cost case from proprietary products, but service costs still matter.

Outcome-based or managed-access agreements can help if the outcome measure, follow-up period, and reporting burden are realistic for NHS services.

Bundled payment may be useful where drug and therapy costs otherwise fall across different budgets, but the bundle has to match how trusts actually deliver care.

NHS infrastructure and workforce

NHS capacity will depend on rooms, monitoring processes, trained staff, and a service specification that trusts can actually use. Developers can work with NHS partners to define the minimum viable setup for safe delivery. Trusts may also need to compare in-house provision with third-party support where that improves capacity or cost.

Training should cover protocol fidelity, safety monitoring, integration, emergency response, and role boundaries. Continuing education will be needed as evidence and regulation change.

Alternative delivery models should be tested for safety, outcomes, patient acceptability, staffing, and cost before they are used as access assumptions.

Implementation pilots

NHS pilots should answer implementation questions: who is referred, who is eligible, how rooms and staff are used, what outcomes improve, and what the care episode costs.

The Ketamine Clinical Treatment Pilot in England at Central and North West London Foundation Trust shows how a new treatment can be tested inside existing care pathways. The pilot uses standard NHS mental-health measures, including PHQ-9, GAD-7, and the Work and Social Adjustment Scale, so outcomes can be tracked through familiar systems. Its 5-7 ketamine-dose protocol, delivered while patients already receive talking therapy, gives the NHS a way to assess clinical effect, service fit, and cost-effectiveness together.

Policymakers can simplify licensing and controlled-substance requirements for psychedelics that receive marketing authorisation, while keeping controls for safety and diversion. Developers, researchers, and payers will still need shared evidence and payment frameworks before those legal changes translate into routine care.

Netherlands

Netherlands: where to focus first

• Use the Netherlands' pragmatic policy experience, but keep the medical pathway distinct: safety, training, payment, and evidence rules still need to be explicit.

• Professional associations and academic centres should define recognised training routes before private training becomes the de facto standard.

• Use existing clinical and research networks for pragmatic studies that can inform ZiN review, insurer contracting, and provider planning.

• Engage ZiN early on cost-effectiveness, budget impact, indirect benefits, and trial design before the Dutch dossier is fixed.

• Work with insurers on payment models that reduce patient cost exposure while covering the full medicine-plus-care episode.

• Use compassionate-use, doctor's-certificate, and research routes carefully while formal registration work continues.

• Professional groups and patient organisations should explain the difference between regulated clinical care and unregulated retreat or self-directed use.

Legal routes before formal approval

The Netherlands has several routes before formal approval, but none is a broad reimbursement pathway. Compassionate use is narrow. The doctor's-certificate route is case-specific and administratively heavy. Research exemptions can support structured evidence generation but still need political, regulatory, and operational support.

The State Committee MDMA report makes these routes relevant, but scalability depends on safety rules, data collection, trained providers, and future payment decisions.

Work with ZiN and insurers early

ZiN's assessment asks whether care is effective, cost-effective, necessary, and feasible. A psychedelic-therapy file should answer those questions for the full treatment offer, not just the molecule.

Engagement should start well before market entry so developers can align Dutch outcomes, cost-effectiveness assumptions, budget impact, and possible societal-value claims with ZiN expectations.

Training and workforce

Therapist training in the Netherlands shows both progress and uncertainty. OPEN Foundation's ADEPT programme is a structured training example, but questions remain about future recognition by medical authorities. Its educational status, rather than formal professional accreditation, shows why national training standards still need to be defined.

Cost and coverage

Dutch financing should make the care episode visible. Medicine cost, therapy time, monitoring, and follow-up may need separate payment routes or a bundled arrangement.

Outcome-based payment agreements link reimbursement to treatment effectiveness and help insurers manage financial risk. Bundled payments can combine medicine and therapy costs into one package for a treatment course or a 6-12 month care period, which simplifies administration and makes the full care episode easier to fund.

Early insurer pilots should test whether higher upfront costs are offset by better outcomes, lower later service use, and improved functioning. The pilot needs data that can support broader reimbursement.

Research implementation

Pragmatic research programmes are the most useful bridge if they combine controlled delivery with systematic evidence generation. They can operate at larger scale than individual access routes while still producing usable data.

A Dutch site network should track outcomes, safety, service use, costs, and patient selection in a way that fits Dutch payer and provider decisions.

Build long-term follow-up into programmes from the start. Follow-up should track clinical outcomes, social functioning, service use, safety, and economic impact. These data help answer the questions payers will keep asking after launch: whether benefits last, who needs retreatment, and which parts of the care model drive value.

Czech Republic

Czech Republic: where to focus first

• Work with SUKL, insurers, and clinical leaders to clarify approval, reimbursement, and service requirements for combined drug-therapy care.

• Build registries and observational studies that track safety, outcomes, retreatment, service use, and patient selection.

• Use risk-sharing only where outcomes and follow-up can be measured credibly.

• Use public-private partnerships to fund trials, evidence infrastructure, training, and early treatment sites.

• Develop training routes through medical associations and academic institutions so services can expand beyond a few expert teams.

• Build on Czech research strength to position the country as a practical pilot market, not only a research hub.

• Use early-access frameworks for treatment-resistant cases only when they also collect evidence that can support broader access.

• Run economic evaluations that test hospital use, medication use, function, productivity, and other service changes where evidence supports them.

• Plan access outside Prague and other major centres through regional partnerships, training, and targeted funding.

Regulatory framework and research base

Czechia has a strong research base and an increasingly relevant policy environment. The implementation question is how that base turns into approved services, reimbursement rules, and trained regional capacity.

Early engagement with SÚKL and payers can clarify approval and reimbursement requirements. Developers should define what evidence is needed for combined drug-therapy treatments, service delivery, and post-launch monitoring.

Evidence generation and implementation

Real-world evidence will matter for acceptance and reimbursement. Pilots should focus on treatment-resistant groups first, with clear data on outcomes, durability, safety, costs, and service requirements.

Cost and coverage

Czech payers face rising personnel costs, chronic-disease pressure, and expensive innovation. Psychedelic therapy will need a disciplined economic case, not only a clinical promise.

Payment models should test whether higher upfront treatment costs are offset by later savings or better outcomes. Economic analyses should include reduced hospitalisation, lower medication use, improved function, and other service-use changes where the evidence supports them. Outcome-based payment may help when payers accept the clinical promise but remain uncertain about durability or total cost.

Infrastructure and training

Ketamine clinics and major-city infrastructure give Czechia a starting point, but broader access will require regional sites, trained staff, and payment rules for the full care episode.

Access outside major cities may need regional hospital partnerships, mobile specialist support, and remote supervision for parts of the pathway that do not require dosing-day presence.

Czechia has strong medical expertise, but dedicated psychedelic-therapy training still needs development through local medical institutions and international partnerships. Training should build on existing medical frameworks while adding psychedelic-specific protocols. Remote support can extend specialist reach in areas where full treatment centres are not yet feasible.

Other access references

What Europe can learn from other models

Australia, Switzerland, the United States, and Canada show different ways to open access before routine reimbursement is solved. The lesson for Europe is to separate legal permission from actual affordability, capacity, and governance.

Australia: legal route before broad reimbursement

Australia's 2023 rescheduling created a legal medical route for authorised psychiatrists to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. The route is important, but it is not the same as broad access.

The useful lesson is governance: authorised prescribers, training expectations, outcome tracking, and clinical protocols need to be clear before patient volume grows.

High treatment costs and limited reimbursement show the access limit. Europe should plan payment and service capacity before relying on a legal route to create availability.

Switzerland: case-by-case medical access

Switzerland shows how case-by-case authorisation can support specialist medical access before broad approval. That route can serve selected patients and generate experience, but it remains hard to scale.

Swiss academic partnerships also show the value of linking controlled access to clinical evidence generation and safety protocols.

The European lesson is to use exceptional access as a learning route, not as a replacement for routine reimbursement and service planning.

United States: fast development, uneven coverage

FDA breakthrough designations have helped U.S. psychedelic programmes move faster through development, but approval speed does not solve coverage, service capacity, or affordability.

Ketamine coverage in parts of the U.S. shows payer acceptance can expand unevenly. Availability still depends on state rules, provider networks, and insurance design.

Europe can borrow the logic of pilots and conditional access, but it should avoid importing a model where patients carry most of the cost.

The U.S. is a useful warning: market activity can grow while access remains expensive and inconsistent.

Canada: special access plus trials

Canada combines clinical trials with Health Canada's Special Access Program. SAP can help patients with serious treatment-resistant conditions, but approvals, supply, and service delivery can still be slow or uneven.

For Europe, the Canadian lesson is to treat special access as a controlled bridge. It should generate learning, but it does not replace a reimbursement route or a scalable service model.

2026 update: practical models are moving from pilots to policy-backed pathways

Newer examples show that access pathways can be built through service regulation, targeted special access, and clearer prescribing standards when governance and safety expectations are explicit.

Policy design and care-model design have to move together.

Implementation takeaways

• Map service requirements directly to regulatory and payer constraints in each market.

• Use phased implementation with explicit governance checkpoints instead of one-step national rollouts.

• Capture operational data early so future reimbursement and scale decisions are not based on assumptions alone.

Sources

• Oregon Psilocybin Services (Oregon Health Authority, 2023-01-02)

• Special Access Program for Drugs (Health Canada, 2026-04-08)

• Checklist for Prescribing Psychiatrists of Psychedelics (Therapeutic Goods Administration (TGA), 2023-09-01)